Endocrine System Diseases  >>  PF-04937319  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-04937319 / Pfizer, PegBio
NCT01933672: Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

Completed
1b
33
US
PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
Pfizer
Type 2 Diabetes Mellitus
03/14
03/14
NCT01044537: A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus

Completed
1
50
US
Placebo, PF-04937319
Pfizer
Type 2 Diabetes Mellitus
05/10
05/10
NCT01272804: Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Completed
1
61
US
PF-04937319, Placebo
Pfizer
Diabetes Mellitus, Type 2, NIDDM
07/11
07/11
NCT02206607: Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

Completed
1
39
US
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Pfizer
Type 2 Diabetes Mellitus
01/15
01/15
NCT02292433: A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Completed
1
12
Japan
PF-04937319 high dose, PF-04937319 low dose, Placebo
Pfizer
Type 2 Diabetes Mellitus
03/15
03/15

Download Options